Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279313 · ClinicalTrials.gov registry record · Phase 3
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
A Phase 3 study of Attention Deficit/Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Active
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
- 20
- Study locations
NCT05279313 is a Phase 3 study of Attention Deficit/Hyperactivity Disorder that is active but no longer recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 680 participants, above the 247-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (175% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT05279313, a Phase 3 study of Attention Deficit/Hyperactivity Disorder, is active but no longer recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate long-term safety exposure
Conditions Studied
Interventions
- DRUG Centanafadine Hydrochloride
Study Locations (20)
California
- Care Access - Beverly Hills
- Proscience Research Group - Culver City
- Sun Valley Research Center, Inc. - Imperial
- Long Beach Clinical Trials Services, Inc - Long Beach
- NRC Research Institute - Orange
- SDS Clinical Trials Inc - Santa Ana
- CMB Clinical Trials - Santee
- Pacific Clinical Research Management Group LLC - Upland
Florida
- Sarkis Clinical Trials - Gainesville
- Direct Helpers Research Center - Hialeah
- Reliable Clinical Research, LLC - Hialeah
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- West Broward Outpatient Site - Lauderhill
Alabama
- Harmonex Neuroscience Research - Dothan
- The Center for Clinical Trials, Inc. - Saraland
Arkansas
- Preferred Research Partners, Inc. - Little Rock
- Woodland International Research Group - Little Rock
Arizona
- Southwest Autism Research and Resource Center - Phoenix
Colorado
- MCB Clinical Research Centers - Colorado Springs
Connecticut
- Mindscapes Counseling LLC DBA Comprehensive Psychiatric Care, PC - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279313
The ClinicalTrials.gov registry entry for NCT05279313 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 247-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (175% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Centanafadine Hydrochloride is the first listed.
NCT05279313 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05279313 about?
NCT05279313 is a clinical study titled "A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.". To evaluate long-term safety exposure
What is the current status of trial NCT05279313?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2022-02-24. Estimated completion is 2026-04-30.
What conditions does trial NCT05279313 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT05279313?
The interventions under investigation include: Centanafadine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05279313?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279313 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.